CYCN

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company emerged as a spinoff focused on developing innovative medicines for serious central nervous system diseases and other conditions through its proprietary soluble guanylate cyclase (sGC) platform technology. Since going public in March 2019, Cyclerion has been advancing multiple drug candidates through various stages of clinical development, with a particular emphasis on neurological disorders that have limited treatment options.